clinical trial · NCT04798768
Effectiveness of the EMPOWER™ Modular Pacing System and EMBLEM™ Subcutaneous ICD to Communicate Antitachycardia Pacing
Tachycardia, VentricularArrhythmia, VentricularmCRM Therapy System
brief summary
The MODULAR ATP Clinical Study is designed to demonstrate safety, performance, and effectiveness of the Modular Cardiac Rhythm Management (mCRM) Therapy System.
started
Jul 20, 2021
primary completion
May 6, 2024
completion
Dec 31, 2030
last updated
Oct 2, 2026
detailed description
The MODULAR ATP Clinical Study will enroll subjects with a standard Implantable Cardioverter Defibrillator (ICD) indication applying international practice guidelines, as well as those who already have an implanted S-ICD System and satisfy the inclusion criteria for this study, while not meeting any exclusion criteria. Subjects will be followed for at least 6 months following mCRM Therapy System implantation.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol